Company Overview - 雷迪克 was established in 2002, focusing on automotive bearing components, with clients including major manufacturers like Geely and SAIC [3] - The company went public on the Shenzhen Stock Exchange in 2017 and has multiple production bases [3] - Recent investments include acquiring 20.41% of Aoyi Technology and establishing a joint venture for robotics development [3] Aoyi Technology Business - Aoyi Technology, founded in 2015, specializes in neural interfaces and robotics, producing products like intelligent prosthetic hands and wearable exoskeletons [3][4] - The intelligent prosthetic hand is the first in China and third globally to receive FDA and CE certifications, with sales in various countries [3][4] Brain-Computer Interface (BCI) Industry - The BCI industry is transitioning from research to commercialization, with significant policy support from the "14th Five-Year Plan" [4] - Current BCI applications are primarily in clinical trials, with limited scalable implementations [4] - Challenges include signal accuracy, real-time decoding, and interdisciplinary integration [4][5] Aoyi's Core Technologies - Aoyi focuses on non-invasive BCI technologies, developing high-precision EEG and EMG systems [6] - Applications include: - Intelligent prosthetic hand systems for upper limb amputees [6] - Rehabilitation systems for patients with upper limb disabilities [6] - Integrated research and diagnostic platforms for EEG and EMG [6] Future Outlook for BCI - The BCI industry is expected to first impact the medical field, particularly in treating neurological disorders, before expanding into industrial and consumer electronics [7] - Aoyi plans to develop tools for clinical neuroscience and address various neurological conditions, including stroke and anxiety disorders [7] Collaboration Between 雷迪克 and Aoyi - 雷迪克 invested 160 million CNY in Aoyi's B3 financing round and co-founded Zhejiang Lei Ao Robotics [7] - The partnership aims to integrate precision transmission components with Aoyi's robotics technology, enhancing production capabilities [7] International Expansion - 雷迪克 plans to invest 30 million USD in a new automotive bearing production facility in Tangier, Morocco, to improve delivery times to European, African, and Middle Eastern clients [8] - The project has completed overseas direct investment registration, with preparations underway [8]

Group 1: R&D and Innovation - R&D expenses decreased in the first three quarters of 2025, aligned with the company's established research plans and progress [1] - The company leverages resources from its Yunnan Province plant extraction laboratory and research institutes in Japan and France to conduct targeted research in various areas, including innovative raw material development and functional cosmetics [1] Group 2: Competitive Advantage - The company's core competitive advantage is a brand trust barrier formed by "medical endorsement + consumer mindset," which is difficult to replicate in the short term [2] - This trust is built on years of deep engagement with hospital channels, professional doctor recognition, and extensive clinical validation data, resulting in a large, loyal customer base of sensitive skin users [2] Group 3: Profitability Improvement - The company's product profitability has improved, primarily due to a focus on brand building and member operation strategies [2] - Strategies include differentiated member operations, maintaining stable pricing, reducing promotional benefits, and streamlining product lines to concentrate resources on core products [2]

Group 1: Financial Performance - In the first three quarters of 2025, the company reported a revenue of 2.265 billion yuan, a year-on-year decrease of 20.70% [2] - The net profit for the same period was 392 million yuan, reflecting a year-on-year decline of 45.69% [2] - Basic earnings per share stood at 0.7327 yuan, down 45.69% compared to the previous year [2] - The weighted average return on net assets was 9.16%, a decrease of 9.20% year-on-year [2] Group 2: Product Overview Refrigeration Products - The company offers a diverse range of refrigeration products, including commercial central air conditioning compressors, refrigeration compressors, and heat pump compressors [3] - The refrigeration compressors are widely used in commercial buildings, food cold chain logistics, and heating applications, meeting various customer needs [3] Air Compression Products - The air compressors serve as core equipment in engineering machinery and are crucial in industries such as pharmaceuticals, chemicals, electronics, and road maintenance [3] - The company is expanding into oil-free air compressor markets, targeting industries with high air quality requirements, such as food and biomedicine [3] Vacuum Products - The vacuum products are primarily used in the photovoltaic and semiconductor industries, with plans to expand into lithium batteries, pharmaceuticals, and chemical manufacturing [4] - The company has begun bulk supply to domestic chip manufacturers, covering both new production lines and the replacement of old vacuum pumps [4] Group 3: Contract Liabilities - There has been an increase in contract liabilities in the first three quarters, primarily due to a rise in advance payments from new orders [4] Group 4: Investor Relations Activity - The investor relations activity included participation from various securities firms and asset management companies, with no undisclosed significant information shared during the event [5]

证券代码：000048 证券简称：京基智农 深圳市京基智农时代股份有限公司 投资者关系活动记录表 编号：2026-001 | | 特定对象调研（含个人投资者来访） 分析师会议 | | --- | --- | | | □媒体采访 业绩说明会 | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | 现场参观 | | | 其他（电话会议） | | | 博时基金 弓琛、王鹤锟、张锦；长安基金 徐小勇；长信基金 王祎杰；富国基金 杨 | | | 波；华夏基金 郑晓辉、吴昊、孙明达；华安基金 朱恒栋；交银施罗德基金 季参平、 | | | 傅爱兵；景顺长城基金 江磊；金元顺安基金 韩辰尧、侯斌；摩根基金 郭晨；摩根 | | | 士丹利基金 李子扬；南方基金 万朝辉；申万菱信基金 龚云华；万家基金 汪洋； | | | 西部利得基金 蒋天宇；易方达基金 朱艳；长城基金 陈良栋；中银基金 赵建忠； | | | 圆信永丰基金 明兴、汪萍；中信保诚基金 王睿；建信养老金管理 官忠涛；中国人 | | | 保资产 周修启；中国人寿资产 王卫华；中再资产管理 赵勇；广东民营投资股份有 | | | 限公司 罗宇晨；红 ...

投资者关系活动记录表 投资者关系活动记录表 创新创造了有利条件。 证券代码：300674 证券简称：宇信科技 北京宇信科技集团股份有限公司 投资者关系活动记录表 编号：2026-001 | 投资者关系活动 | 特定对象调研 媒体采访 | 分析师会议 | | | | --- | --- | --- | --- | --- | | 类别 | 业绩说明会 路演活动 | 新闻发布会 | | | | | 现场参观 其他（券商策略会、电话会议） | | | | | 参与机构名称 | 机构名称 | 机构名称 | 机构名称 | 机构名称 | | | 诺安基金 | 华商基金 | 华安基金 | 鹏华基金 | | | 华泰资管 | 中海基金 | 国富人寿 | 申万宏源证券 | | | 摩根士丹利 | 长盛基金 | 博时基金 | 中泰证券 | | | 复兴保德信 | 中国人寿资管 | 砥俊资管 | 中信证券 | | | 兴业银行 | 农银理财 | 海金投资 | 中信建投证券 | | | 国泰海通证券 | 东方证券 | 伏明资管 | 先锋基金 | | | 安联基金 | 富荣基金 | 禾驹私募 | 三鑫资管 | | | ...

Sales Performance - In 2024, the sales of all-steel giant tires by rim diameter were as follows: 49 inches - 5,974 units, 51 inches - 4,201 units, 57 inches - 5,594 units, and 63 inches - 302 units [2] - The weight of the all-steel giant tires varies by size: 49 inches approximately 1.5 tons, 51 inches between 1.5 to 3.0 tons, 57 inches between 3 to 4.5 tons, and 63 inches between 4.5 to 6 tons [2] Cost Structure - The operational management cost of mining tires consists of three main components: tire consumption cost (70%), direct labor, and indirect expenses (each around 10%) [3] Revenue Composition - In 2024, the overseas sales revenue composition was: Europe - 69.82%, Asia - 15.77% [4] Business Model - The mining tire operational management business includes tire supply and on-site project teams providing comprehensive lifecycle management services, enhancing production safety and efficiency for mining companies [5] Competitive Landscape - The all-steel giant tire market is dominated by three major international brands, with the company holding a competitive position in terms of market share and service capabilities [6] - The company maintains a strong presence in the Russian market despite geopolitical tensions, supported by long-term contracts with major clients [7] Payment and Settlement - The company uses cross-border trade in RMB for settlements with Russian clients, ensuring stable and smooth transaction processes [8] Investment Projects - The company’s fundraising projects include: all-steel giant tire expansion (3 years), automation upgrades (2 years), and R&D center construction (3 years) [9] Market Development - As of June 30, 2025, the company signed orders for 4,790 all-steel giant tires worth approximately 337 million RMB, with ongoing negotiations for additional orders [10] Strategic Partnerships - The company has established strong relationships with industry leaders like Zijin Mining and Jiangxi Copper, enhancing mutual trust and collaboration [11]

Group 1: Company Overview and Business Focus - The company is focused on developing next-generation edge brain-machine interface algorithm chips and advancing mixed biometric and brain signal collaborative analysis [2] - The joint venture is currently in the preparation stage for business registration [2] Group 2: Performance Guidance and Targets - The company has set performance assessment targets for 2026 based on the 2025 restricted stock incentive plan and employee stock ownership plan [2] - Strategies to achieve growth include deepening technology applications, expanding market reach, enhancing brand influence, and increasing product and service competitiveness [2] Group 3: Incentive Plan and Acquisitions - The stock incentive plan specifies that the operating results of newly acquired companies will not be included in the performance assessment during the incentive period [3] - The impact of these acquisitions on the company's net profit and operating income will be calculated separately [3] Group 4: Competitive Advantages - The company leverages long-term accumulation in cognitive space computing and focuses on AI BioCV TinyML edge model development [3] - The integration of perception, analysis, and decision-making capabilities into edge devices establishes a solid technical foundation for wearable and scenario-based applications of non-invasive brain-machine interfaces [3] Group 5: Team Strengths and Market Position - The team has extensive experience in the industry, with a strong data accumulation in consumer scenarios and a stable performance indicator [3] - The founding and R&D team includes members from Silicon Valley and renowned U.S. institutions, covering multiple fields such as chip design and algorithm development [3] Group 6: Currency and Risk Management - The company has not yet adopted digital RMB for cross-border settlements, and foreign income constitutes a significant portion of its revenue [3] - To mitigate currency fluctuation risks, the company employs global supply chain strategies and local operations of subsidiaries, along with forward foreign exchange contracts [3]

Group 1: Digital Currency Expansion - The digital RMB has expanded from M0 to M1, marking a significant shift towards large-scale implementation and indicating the government's commitment to promoting its use [3] - The transition allows digital RMB to possess deposit attributes, enabling it to cover most functions of traditional RMB, particularly in corporate settlement scenarios [3] - The digital RMB's traceability and immutability features are expected to play a crucial role in anti-money laundering and fraud prevention [3] Group 2: IT System Adjustments - Banks will need to initiate large-scale IT system upgrades to accommodate the transition from M0 to M1, including adjustments to payment systems and account structures [3] - The integration of digital RMB into existing banking systems will require modifications to ensure compatibility with its encrypted attributes [3] Group 3: Cross-Border Applications - Future cross-border applications of digital RMB may involve creating a unified ecosystem, allowing other countries to issue corresponding digital currencies based on currency swap agreements [4] - The digital RMB aims to simplify cross-border transactions by eliminating complex intermediaries, enhancing transaction transparency and compliance [4] Group 4: Policy and Regulatory Signals - Key signals to watch for include the central bank's issuance of detailed regulations for settlement and deposit-related policies for the M1 phase of digital RMB [4] - State-owned enterprises are expected to be the first to pilot the use of digital RMB in payroll and inter-company settlements, marking a significant step towards its widespread adoption [4] Group 5: Core Objectives and Risks - While one of the primary goals of digital RMB is to bypass SWIFT and enhance cross-border transaction security, it also aims to address domestic settlement needs and compete with existing payment platforms [5] - The issuance mechanism of digital RMB is based on national credit, differentiating it from cryptocurrencies like Bitcoin, which lack sovereign backing [5]

Group 1: Industry Outlook - The blood products industry is expected to experience significant growth due to factors such as economic development, aging population, and increased clinical demand for blood products [1] - In 2023 and 2024, the industry is projected to see a supply-demand mismatch, with a 5% increase in plasma collection expected in the first half of 2025 [2] Group 2: Company Performance and Projections - The company anticipates a cash dividend of approximately CNY 256 million for 2024, representing 41.79% of the net profit attributable to shareholders for 2023 [5] - For 2025, the expected cash dividend remains at CNY 256 million, accounting for 34.33% of the net profit for 2024 [6] - In the first three quarters of 2025, the company's revenue and net profit attributable to shareholders decreased due to capacity expansion efforts [7] Group 3: Production and Capacity - The company expects to collect nearly 1,600 tons of plasma in 2025, with a projected output of over 1,400 tons [8] - The total production capacity has been expanded to over 3,000 tons following the completion of capacity upgrades in 2025 [7] Group 4: Research and Development - The company is advancing the development of the fourth generation of immunoglobulin, with expected regulatory approval for new indications by 2027 [9][10] - The company is also focusing on the development of human coagulation factors, with anticipated approvals for new products in 2027 [10] Group 5: Market Expansion and Control Transfer - The company is actively pursuing overseas market opportunities, with plans for regulatory registration and export sales [3] - The transfer of control to China National Biological is in progress, with significant steps taken towards finalizing the transaction by June 30, 2026 [4][12] Group 6: Infrastructure and Product Range - The company operates a total of 38 plasma collection stations, ranking third in the industry [11] - The product range includes 11 varieties across multiple specifications, also placing the company third in the industry [11]

Company Overview - Baolait Medical Technology Co., Ltd. was established in 1993, focusing on the R&D, production, and sales of medical devices. It is recognized as a "National Industrialization Base for Multi-parameter Monitors" and a "National Champion Enterprise" in manufacturing [1][2]. - The company’s monitoring equipment is utilized in thousands of medical institutions, offering a wide range of products including integrated monitors, modular monitors, and portable monitors, as well as infusion pumps and ECG machines [1][2]. Product Development and Innovation - The company aims to enhance its monitoring products by integrating smart technology to address clinical needs and develop differentiated solutions [3]. - The D800 series of hemodialysis devices, featuring single, double, and triple pump models, supports real-time monitoring of vital signs and includes IoT capabilities for remote management [4]. Market Growth and Trends - The hemodialysis market is projected to grow, with 1.027 million patients expected in 2024, maintaining a compound annual growth rate (CAGR) of approximately 12% over the past decade [6]. - The domestic market for hemodialysis equipment saw sales growth in the first three quarters of 2025, driven by hospital operations and centralized procurement [6]. Regulatory Impact - The "Urological Medical Service Pricing Project Guidelines" issued in June 2025 will include monitoring parameters in the pricing of hemodialysis, benefiting the D800 series which meets these new requirements without additional modules [7]. Peritoneal Dialysis Market - The peritoneal dialysis market is also expanding, with 156,400 patients projected in 2024 and a CAGR of over 10% in the last decade. Challenges include cost and safety concerns, but increased policy support is expected to drive adoption [8][9]. - The company has launched automated home peritoneal dialysis machines and disposable tubing, with ongoing efforts to enhance marketing strategies for these products [9]. New Product Launches - Recent product launches include the D800 series, P series modular monitors, home peritoneal dialysis machines, and various other innovative medical devices, some of which have received industry accolades [10]. - The D800Plus is noted as the first domestic triple pump model, improving dialysis treatment outcomes through advanced technology [10]. Conclusion - Baolait Medical Technology is positioned to leverage its technological advantages in a growing market, supported by favorable policies and a commitment to innovation in medical devices [5][6][7].